Biotech Beam Therapeutics has dosed the first patient in a Phase I/II study of its base-edited CAR-T therapy in relapsed or refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.

The partnership with Chinese biotech Cellular Biomedicine Group will cost J&J $245 million upfront and give it access to two differentiated CAR-T therapies for diffuse large B-cell lymphoma.

Leaked data from the Phase III CARTITUDE-4 trial showed Johnson & Johnson’s and Legend Biotech’s Carvykti (ciltacabtagene autoleucel) performed much better than expected in patients with multiple myeloma (MM), according to reporting by STAT News.

CAR-T cell therapy, or chimeric antigen receptor T cell therapy, is best known for its application in oncology, where the results have been life-changing for patients. The therapy for autoimmune diseases made headlines in September 2022 when five patients with systemic lupus erythematosus (SLE) were confirmed to be in remission for an average of eight months after treatment.

Autolus Therapeutics is calling the Phase II FELIX trial, assessing its next-generation CAR-T therapy obe-cel for leukemia, a win after an interim analysis revealed an overall remission rate of 70%.

The promised layoffs at Atara Biotherapeutics have begun weeks after the Bay Area company announced plans to terminate 20% of its staff under a new corporate strategy focused on the innovation within the company’s pipeline.

A study published this month in Science discusses data that may support a devious alter ego of T-cells present within colorectal cancer tumors.

Genentech, a member of the Roche group, announced new data on Thursday related to the company’s investigational CD20xCD3 T-cell engaging bispecific antibody glofitamab, which is intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).